Beyond CD30: Dual‐Targeting of Malignant and Regulatory T Cells by Brentuximab Vedotin Remodels the Lymphoma Microenvironment and Overcomes Resistance via BCL2 Inhibition in Mycosis Fungoides

ABSTRACT Mycosis fungoides (MF), the most common subtype of cutaneous T cell lymphoma (CTCL), has a poor prognosis in advanced stages. Brentuximab vedotin (BV), a CD30‐targeting antigen‐drug conjugate approved for CD30+ MF following prior systemic treatment, still exhibits resistance with unclarifie...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Yi Jiang, Pan Lai, Mingjia Li, Yujie Wen, Mengzhou Cao, Yu Xiao, Zhuojing Chen, Jingru Sun, Yang Wang
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2026-05-01
Edice:	Advanced Science
Témata:	BCL2 brentuximab vedotin interferon response mycosis fungoides tumor microenvironment
On-line přístup:	https://doi.org/10.1002/advs.202517353
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!